Jinzanghuang Tibet (GREY:JZHG)

WEB NEWS

Monday, August 6, 2012

Deal Flow
Item 3.02                      Unregistered Sale of Equity Securities

On July 31, 2012 the Registrant sold 10,000,000 shares of common stock to seven unrelated individuals in a private offering.  The purchase price for the shares was $.10 per share, or a total of $1 million.  The shares were sold to individuals who are accredited investors and were purchasing for their own accounts.  The offering, therefore, was exempt from registration under the Securities Act of 1933 pursuant to Section 4(2) and Section 4(5) of the Securities Act.

Tuesday, June 26, 2012

Auditor trail
Item 4.01                      Change in Registrant’s Certifying Accountant
 
On June 21, 2012 the Board of Directors of Jinzanghuang Tibet Pharmaceuticals, Inc.  approved the dismissal of De Joya Griffith & Company, LLC from its position as the principal independent accountant for Jinzanghuang Tibet Pharmaceuticals.
 
The Board of Directors engaged De Joya Griffith & Company, LLC as principal independent accountant on July 13, 2011.  The audit report of De Joya Griffith & Company, LLC on Jinzanghuang Tibet Pharmaceutical’s financial statements for the fiscal year ended June 30, 2011 did not contain an adverse opinion or disclaimer of opinion or qualification or modification.  De Joya Griffith & Company, LLC did not, during the applicable periods, advise Jinzanghuang Tibet Pharmaceuticals of any of the enumerated items described in Item 304(a)(1)(iv) of Regulation S-K.
 
Jinzanghuang Tibet Pharmaceuticals and De Joya Griffith & Company, LLC have not, during Jinzanghuang Tibet Pharmaceuticals’s most recent fiscal year or any subsequent period through the date of dismissal, had any disagreement on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreement, if not resolved to De Joya Griffith & Company, LLC’s satisfaction, would have caused De Joya Griffith & Company, LLC to make reference to the subject matter of the disagreement in connection with its reports.
 
Jinzanghuang Tibet Pharmaceuticals has requested De Joya Griffith & Company, LLC to furnish a letter addressed to the Securities Exchange Commission stating whether or not De Joya Griffith & Company, LLC agrees with the statements in this Form 8-K.  A copy of the letter is filed as an exhibit to this 8-K.
 
On June 21, 2012 Jinzanghuang Tibet Pharmaceuticals retained Stan Jeong-Ha Lee, CPA to audit Jinzanghuang Tibet Pharmaceuticals’ financial statements for the year ended June 30, 2012.  At no time during the two most recent fiscal years and the subsequent interim period through June 21, 2012, the date of the engagement, did Jinzanghuang Tibet Pharmaceuticals consult with Stan Jeong-Ha Lee, CPA regarding any matter of the sort described above with reference to De Joya Griffith & Company, LLC, any issue relating to the financial statements of Jinzanghuang Tibet Pharmaceuticals, or the type of audit opinion that might be rendered for Jinzanghuang Tibet Pharmaceuticals.

Monday, May 21, 2012

Comments & Business Outlook
JINZANGHUANG TIBET PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME
(Unaudited)
 
                                 
     
Three Months Ended March 31,
     
Nine Months Ended March 31,
 
      2012        2011        2012        2011  
 REVENUE                                
    Pharmaceutical products
  $ -     $ -     $ -     $ 26,997  
    Services
    2,712,438       1,329,240       7,936,203       1,881,954  
      2,712,438       1,329,240       7,936,203       1,908,951  
COST OF SALES
                               
    Pharmaceutical products
    -       -       -       24,594  
    Services
    442,447       63,436       1,117,628       132,013  
    Business and sales related tax
    152,552       -       430,694       -  
      594,999       63,436       1,548,322       156,607  
                                 
GROSS PROFIT
    2,117,439       1,265,804       6,387,881       1,752,344  
                                 
COSTS AND EXPENSES
                               
    General and administrative expenses
    128,483       113,489       315,636       212,226  
OPERATING INCOME
    1,988,956       1,152,315       6,072,245       1,540,118  
                                 
OTHER INCOME
    6,583       -       13,986       -  
                                 
INCOME BEFORE INCOME TAX
    1,995,539       1,152,315       6,086,231       1,540,118  
                                 
INCOME TAX
    578,288       289,451       1,451,583       389,511  
                                 
NET INCOME
    1,417,251       862,864       4,634,648       1,150,607  
                                 
LESS: NET INCOME ATTRIBUTABLE TO NON-CONTROLLING INTERESTS
    70,813       43,697       228,184       58,134  
                                 
NET INCOME ATTRIBUTABLE TO THE COMPANY
    1,346,438       819,167       4,406,464       1,092,473  
                                 
OTHER COMPREHENSIVE INCOME
                               
    Foreign currency translation gain, net of tax
    1,528       21,289       129,604       61,227  
                                 
COMPREHENSIVE INCOME
    1,347,966       840,456       4,536,068       1,153,700  
                                 
LESS: OTHER COMPREHENSIVE INCOME ATTRIBUTABLE TO NON-CONTROLLING INTERESTS
    1,588       3,438       7,992       30,019  
                                 
COMPREHENSIVE INCOME ATTRIBUTABLE TO THE COMPANY
  $ 1,346,378     $ 837,018     $ 4,528,076     $ 1,123,681  
                                 
Basic and diluted earnings per common share
  $ 0.03     $ 0.02     $ 0.11     $ 0.03  
                                 
Weighted average number of shares outstanding
    40,665,063       40,665,063       40,665,063       40,665,063  

Sunday, February 19, 2012

Comments & Business Outlook
 
 
 
 
 
                       
       
Six Months Ended December 31,
 
   
2011
   
2010
   
2011
   
2010
 
REVENUE
                       
    Pharmaceutical products
  $ -     $ -     $ -     $ 26,673  
    Services
    2,659,182       553,038       5,223,765       553,038  
      2,659,182       553,038       5,223,765       579,711  
COST OF SALES
                               
    Pharmaceutical products
    -       -       -       24,299  
    Services
    441,349       68,872       675,181       68,872  
    Business and sales related tax
    148,830       -       278,142       -  
      590,179       68,872       953,323       93,171  
                                 
GROSS PROFIT
    2,069,003       484,166       4,270,442       486,540  
                                 
COSTS AND EXPENSES
                               
    General and Administrative Expenses
    72,514       64,858       187,153       98,737  
OPERATING INCOME
    1,996,489       419,308       4,083,289       387,803  
                                 
OTHER INCOME
    6,348       -       7,402       -  
                                 
INCOME BEFORE INCOME TAX
    2,002,837       419,308       4,090,691       387,803  
                                 
INCOME TAX
    397,729       106,993       873,295       100,060  
                                 
NET INCOME
    1,605,108       312,315       3,217,396       287,743  
                                 
LESS: NET INCOME ATTRIBUTABLE TO NON-CONTROLLING INTERESTS
    74,695       15,995       157,371       14,437  
                                 
NET INCOME ATTRIBUTABLE TO THE COMPANY
    1,530,413       296,320       3,060,025       273,306  
                                 
OTHER COMPREHENSIVE INCOME
                               
    Foreign currency translation gain, net of tax
    56,457       20,011       128,076       39,938  
                                 
COMPREHENSIVE INCOME
    1,586,870       316,331       3,188,101       313,244  
                                 
LESS: OTHER COMPREHENSIVE INCOME ATTRIBUTABLE TO NON-CONTROLLING INTERESTS
    2,823       10,512       7,516       26,581  
                                 
COMPREHENSIVE INCOME ATTRIBUTABLE TO THE COMPANY
  $ 1,584,047     $ 305,819     $ 3,180,585     $ 286,663  
                                 
Basic and diluted earnings per common share
  $ 0.04     $ 0.01     $ 0.08     $ 0.01  
                                 
Weighted average number of shares outstanding
    40,665,063       40,665,063       40,665,063       40,665,063

The increase in revenues was primarily caused by a marked increase in per store revenue, which we attribute to growing awareness of our product line.


Monday, December 12, 2011

Liquidity Requirements

Despite our sizeable cash reserves, we borrowed $29,460 from a related party during the quarter ended September 30, 2011. The loans are taken in order to obtain U.S. Dollars to pay our expenses in the United States, including accounting and legal expenses and the expenses that attend the listing of our common stock on the U.S. markets. The procedure required in order to obtain government approval of a conversion of Renminbi into Dollars is time-consuming and laborious. For that reason, until we complete a financing in U.S. Dollars or obtain some other source of U.S. Dollars, we will continue to borrow Dollars from related parties as needed.

Over the long term, our expectation is that we will utilize our capital resources as well as any additional investments that we secure in order to expand our presence in the market for Tibetan medicine. At the present time, however, we are able to operate profitably without significant additional investment. Moreover, our observation of the equity markets indicates that we would be unlikely to obtain financing on favorable terms at this time. Accordingly, our near term plan is to continue the program that we initiated during the past year, utilizing the resources available to us.


Wednesday, November 23, 2011

Comments & Business Outlook
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)
 
(Unaudited)
 
             
   
Three Months Ended September 30,
 
   
2011
   
2010
 
REVENUE
           
    Pharmaceutical products
  $ -     $ 26,673  
    Services
    2,564,583       -  
      2,564,583       26,673  
COST OF SALES
               
    Pharmaceutical products
    -       24,299  
    Services
    233,832       -  
    Business and sales related tax
    129,312       -  
      363,144       24,299  
                 
GROSS PROFIT
    2,201,439       2,374  
                 
COSTS AND EXPENSES
               
     General and Administrative Expenses
    114,639       33,879  
OPERATING INCOME (LOSS)
    2,086,800       (31,505 )
                 
OTHER INCOME
    1,054       6,933  
                 
INCOME (LOSS) BEFORE INCOME TAX
    2,087,854       (24,572 )
                 
INCOME TAX
    475,566       -  
                 
NET INCOME (LOSS)
    1,612,288       (24,572 )
                 
LESS: NET INCOME ATTRIBUTABLE TO NON-CONTROLLING INTERESTS
    82,676       (1,558 )
                 
NET INCOME (LOSS) ATTRIBUTABLE TO THE COMPANY
    1,529,612       (23,014 )
                 
OTHER COMPREHENSIVE INCOME
               
   Foreign currency translation gain, net of tax
    71,619       19,927  
                 
COMPREHENSIVE INCOME (LOSS)
    1,601,231       (3,087 )
                 
LESS: OTHER COMPREHENSIVE INCOME ATTRIBUTABLE TO NON-CONTROLLING INTERESTS
    4,693       16,069  
                 
COMPREHENSIVE INCOME (LOSS) ATTRIBUTABLE TO THE COMPANY
  $ 1,596,538     $ (19,156 )
                 
Basic and diluted earnings (loss) per common share
  $ 0.04     $ (0.00 )
                 
Weighted average number of shares outstanding
    40,665,063       40,665,063

Our sauna store program began in October 2010 with a trial group of 50 sauna stores. At the end of December 2010 we added another 50 stores to our program, and then added another 50 at the end of March 2011. As a result, our revenue from advisory services increased from quarter to quarter. The revenue growth was roughly proportionate to the growth in number of stores, except that the third quarter was particularly profitable. This occurred because the Chinese Spring Festival in February affords most Chinese workers from one to two weeks of vacation, during which time the sauna stores experience a sharp increase in business.


Liquidity Requirements

To date our operations have been funded by the contributions to capital by our founders and the net cash provided by our operations. As a result, at September 30, 2011 we had no bank debt and only a $65,370 obligation to a related party. At the same time, we had $3,632,284 in cash at September 30, 2011 as well as working capital totaling $4,292,377, an increase of $1,679,480 since our last fiscal year ended on June 30, 2011. So our capital resources are more than sufficient to fund our operations for the coming year as they are currently structured.

Over the long term, our expectation is that we will utilize our capital resources as well as any additional investments that we secure in order to expand our presence in the market for Tibetan medicine. At the present time, however, we are able to operate profitably without significant additional investment. Moreover, our observation of the equity markets indicates that we would be unlikely to obtain financing on favorable terms at this time. Accordingly, our near term plan is to continue the program that we initiated during the past year, utilizing the resources available to us.


Thursday, February 17, 2011

Comments & Business Outlook
JINZANGHUANG TIBET PHARMACEUTICALS, INC.
 
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)
 
(Unaudited)
 
                           
         
SIX MONTHS ENDED DECEMBER 31,
 
     
2010
   
2009
   
2010
   
2009
 
                           
REVENUE
                         
 
-Pharmaceutical products
  $ -     $ 323,536     $ 26,673     $ 548,486  
 
-Services
    553,038       -       553,038       -  
        553,038       323,536       579,711       548,486  
                                   
COSTS OF REVENUE
                               
 
-Pharmaceutical product sales
    -       219,860       24,299       391,716  
 
-Services
    68,872       -       68,872       -  
        68,872       219,860       93,171       391,716  
                                   
GROSS PROFIT
    484,166       103,676       486,540       156,770  
                                   
COSTS AND EXPENSES
                               
     General and Administrative Expenses
    64,858       60,958       98,737       145,428  
                                   
INCOME (LOSS) BEFORE INCOME TAX
    419,308       42,718       387,803       11,342  
                                   
INCOME TAX
    106,993       16,875       100,060       19,111  
                                   
NET INCOME (LOSS)
    312,315       25,843       287,743       (7,769 )
                                   
LESS: NET INCOME ATTRIBUTABLE TO NONCONTROLLING INTERESTS
    15,995       2,489       14,437       2,665  
                                   
NET INCOME (LOSS) ATTRIBUTABLE TO THE COMPANY
    296,320       23,354       273,306       (10,434 )
                                   
OTHER COMPREHENSIVE INCOME (LOSS)
                               
   Foreign currency translation adjustment
    20,011       21       39,938       1,365  
                                   
COMPREHENSIVE INCOME (LOSS)
    316,331       23,375       313,244       (9,069 )
                                   
LESS: OTHER COMPREHENSIVE INCOME ATTRIBUTABLE TO NONCONTROLLING INTERESTS
    10,512       -       26,581       36  
                                   
COMPREHENSIVE INCOME (LOSS) ATTRIBUTABLE TO THE COMPANY
  $ 305,819     $ 23,375     $ 286,663     $ (9,105 )
                                   
                                   
                                   
Basic and diluted earnings per common share
  $ 0.01     $ 0.00     $ 0.01     $ (0.00 )
                                   
Weighted average number of shares outstanding
    40,665,063       40,645,063       40,665,063       40,645,063  

On October 8, 2010, Leling JZH entered into a joint venture with Shandong JZH to market to the sauna store industry. Leling JZH entered into an agency agreement with Shenyang Jintao Technology Co., Ltd., which has introduced 50 sauna stores to Shandong JZH and Leling JZH. Shandong JZH sells its Tibetan medicine products to the sauna stores and Leling JZH provides training service to each store to coach how to provide sauna service through using the products sold byShandong JZH. At each month end, each store sends a usage record to Leling JZH. Leling JZH also makes a physical inventory count quarterly to compare remaining inventory with the quantity delivered by Shandong JZH. According to the agreement signed with each store, once products are used, each sauna store will pay 40% of the total sauna service fee to Leling JZH. This arrangement provides Leling JZH with a revenue stream for which it incurs very little direct cost, as the product manufacture and distribution is entirely the responsibility of Shandong JZH. In addition, entry into this new market has not forced us to incur significant start-up costs, as we have used the same employees and same facilities for the sauna market as carried on our prior product distribution activities. On October 8, 2010, Leling JZH entered into a joint venture with Shandong JZH to market to the sauna store industry. Leling JZH entered into an agency agreement with Shenyang Jintao Technology Co., Ltd., which has introduced 50 sauna stores to Shandong JZH and Leling JZH. Shandong JZH sells its Tibetan medicine products to the sauna stores and Leling JZH provides training service to each store to coach how to provide sauna service through using the products sold byShandong JZH. At each month end, each store sends a usage record to Leling JZH. Leling JZH also makes a physical inventory count quarterly to compare remaining inventory with the quantity delivered by Shandong JZH. According to the agreement signed with each store, once products are used, each sauna store will pay 40% of the total sauna service fee to Leling JZH. This arrangement provides Leling JZH with a revenue stream for which it incurs very little direct cost, as the product manufacture and distribution is entirely the responsibility of Shandong JZH. In addition, entry into this new market has not forced us to incur significant start-up costs, as we have used the same employees and same facilities for the sauna market as carried on our prior product distribution activities.

Leling Jinzanghuang continues to sell products designed to provide health protection as its base business. During the six months ended December 31, 2010 it also offered puer tea for sale. We consider the market prospects to be hopeful; so the Company is seeking more customers step by step. During the six months ended December 31, 2010, however, product sales remained low, with no sales at all during the quarter ended December 31, 2010, as we lack the capital necessary to fund a market surge. During the six months ended December 31, 2010 product sales, all of which were made to two customers, contributed only $27,123 to our revenue. In contrast, during the six months ended December 31, 2009, our sales of products manufactured by Shandong Jinzanghuang yielded $548,486 in revenue.

Our operating results for the three and six month periods ended December 31, 2010 were superior to those of the prior year periods, however, since we introduced a second revenue stream in October 2010. We now have arrangements with 50 sauna stores, where we have trained the staff to utilize the products they purchase from Shandong JZH in the sauna services they perform. In exchange for training and advice, we receive 40% of the revenue from the stores. This new business yielded $553,038 in revenue during the three and six month periods ended December 31, 2010. The cost of the sales consists almost entirely of the $1,203 per store fee that we pay to Shenyang Jintao Technology Co., Ltd., which serves as our agent in managing this business, plus the salary of our training staff. As a result, our gross margin for the six months ended December 31, 2010 was 84%. During the six months ended December 31, 2009, we achieved a 28% gross margin.


Liquidity Requirements

Our business plan contemplates that we will obtain $5 million to $10 million in additional capital during 2010 and 2011.  The funds are needed in order to:
 
  ● Relocate our headquarters from Shandong to Beijing, where we will have greater access to marketing channels;

 
  ● Implement our direct marketing program, including development of an online presence;

 
  ● Acquire the rights to pharmaceuticals and nutraceuticals that will complement our existing product line;

 
  ● Carry on clinical trials of pharmaceuticals required to obtain SFDA approval;

 
  ● Establish franchisees throughout China; and

 
  ● Implement an advertising and marketing program adequate to assure us of substantial market presence.

 
Our plan is to sell a portion of our equity in order to obtain the necessary funds, which will reduce the equity share of our existing shareholders.  To date, however, we have received no commitment from any source for funds.


Monday, September 13, 2010

CFO Trail
On August 26, 2010 Yang An resigned from his position as a member of the Registrant’s Board of Directors and as an officer of the Registrant. On the same date Zeng Yiling resigned from his position as the Registrant’s Chief Financial Officer.

Sunday, March 29, 2009

Reverse Merger Activity

Leling Jinzanghuang Biotech Co., Ltd, a Tibetan health products company,  goes public via a reverse merger transaction on January 12, 2009.  Upon completion of the Share Exchange, there were 40,644,780 shares common stock issued and outstanding. 

The company has yet to generate any significant revenues, as the market for Tibetan pharmaceuticals in China is only a very small portion of the overall medical market in China. The annual production of Tibetan medicine amounts to approximately 1500 tons with more than 293 items marketed.  However, the growth rate of the market for Tibetan pharmaceuticals is substantial. One factor spurring growth has been the willingness of Chinese regulators to accredit products based on Tibetan medicine. At the present time, this accreditation includes:

  • 14 products that have been listed on the Protected Chinese Traditional Medicine List;
  • 24 products that have been included in the National Medicine Index;
  • 218 products that have been certified by the SFDA; and
  • 20+ products that have registered trademarks in China.

Source: SEC Form 8K (January 12, 2009)


Liquidity Requirements

Our business plan contemplates that we will obtain $5 million to $10 million in additional capital during 2009 and 2010.

Source: SEC Form 8K (January 12, 2009. Page 12)



Market Data powered by QuoteMedia. Terms of Use